Dr. Michael Rodriguez -- Pharmaceutical Payment Report

This page provides a comprehensive transparency report for Dr. Michael Rodriguez, a Rheumatology physician based in City, LA. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Michael Rodriguez has received $18,052.05 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.

Physician Profile

The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.

Payment Summary

Dr. Michael Rodriguez has received a total of $18,052.05 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $18,052.05 per transaction.

Payment Breakdown by Category

The following table shows how Dr. Michael Rodriguez's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.

Payment CategoryAmountDescription
Consulting Fees$18,052.05Advisory board participation, clinical consulting, and expert opinion services

The largest payment category for Dr. Michael Rodriguez is Consulting Fees, accounting for 100% ($18,052.05) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.

Pharmaceutical Company Relationships

The following pharmaceutical and medical device companies have made payments to Dr. Michael Rodriguez. Click on any company name to view their full physician payment profile and spending patterns.

CompanyTotal PaidTransactions
Amgen Inc$18,052.051

Dr. Michael Rodriguez has a financial relationship with Amgen Inc, receiving $18,052.05 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.

AI Transparency Analysis

The following analysis was generated by artificial intelligence based on Dr. Michael Rodriguez's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.

Michael Rodriguez has received $18.1K across 1 pharmaceutical payments as a Rheumatology physician in City, LA. Top paying companies include Amgen Inc ($18.1K). Dr. Rodriguez received a single payment of $18,052 in 2024, indicating a significant engagement. The entire payment came from Amgen Inc., suggesting a focused relationship with this pharmaceutical company. This payment was categorized as 'consulting', highlighting the nature of the engagement.

Patient Guidance: Questions to Ask Your Doctor

If Dr. Michael Rodriguez is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:

Consumers should be aware that this doctor has received a large payment from a single drug company for consulting services, and consider this information when evaluating their treatment options. Always feel free to ask your doctor directly about their pharmaceutical relationships.

Peer Comparison: How Dr. Michael Rodriguez Compares to Other Rheumatology Physicians

For a Rheumatologist, a single large payment from one company is less common than multiple smaller payments from various sources.

Recent Payment Records

The following table shows the most recent pharmaceutical industry payments recorded for Dr. Michael Rodriguez in the CMS Open Payments database. Click on any payment to view the full report.

CompanyAmountTypeDrug/DeviceDateConflict Level
Amgen Inc$18,052.05consultingN/A2024-12-16Not Assessed

Frequently Asked Questions About Dr. Michael Rodriguez's Pharma Payments

Below are common questions patients ask about physician pharmaceutical payment data.

How much pharma money has Michael Rodriguez received?

Michael Rodriguez has received a total of $18.1K across 1 payments from pharmaceutical companies. This data is publicly reported under the CMS Open Payments (Sunshine Act) program.

Is Michael Rodriguez taking too much pharma money?

Michael Rodriguez has received $18.1K in pharmaceutical payments. Whether this is "too much" depends on the physician's specialty (Rheumatology), the types of payments, and how they compare to peers. The largest payment category is consulting ($18.1K). Payment does not imply wrongdoing, but patients should be aware and can ask their doctor directly.

What pharma companies pay Michael Rodriguez?

The top pharmaceutical companies paying Michael Rodriguez are: Amgen Inc ($18.1K). These payments cover various categories including consulting, meals, speaking fees, and research grants.

What kinds of payments does Michael Rodriguez receive?

Michael Rodriguez's payments by type: consulting: $18.1K. Consulting fees suggest active advisory roles with pharmaceutical companies.

Should I switch doctors because of pharma payments?

Pharma payments alone are not typically reason to switch doctors. Many payments are routine (like meals at educational events) and do not indicate compromised care. Focus on: (1) whether your doctor explains treatment options clearly, (2) whether generic alternatives are discussed, (3) the overall pattern of payments, not individual transactions. If you have concerns, ask your doctor directly.

How do Michael Rodriguez's payments compare to other Rheumatology doctors?

To compare, look at the total amount ($18.1K), number of payments (1), and the types of payments received. Rheumatology physicians may receive different payment amounts depending on subspecialty, geographic location, and academic affiliation. Use CMS Open Payments data to compare across the specialty.

How can I verify Michael Rodriguez's payment data?

You can verify this data directly through the CMS Open Payments database at openpaymentsdata.cms.gov. Search by physician name or NPI number (1053775186). All data is reported by pharmaceutical companies and verified by CMS. DoctorPharmaData aggregates this public data for easier access.

Do pharma payments affect prescribing quality?

Research published in JAMA Internal Medicine and other peer-reviewed journals shows a statistical association between pharmaceutical payments and prescribing patterns. However, correlation does not equal causation. Many physician-industry interactions are legitimate (research, education, advisory boards). The Sunshine Act was created to promote transparency so patients can make informed decisions.

What stands out about Michael Rodriguez's pharma payment profile?

The doctor has only one recorded payment, making it difficult to establish a comprehensive payment history. Michael Rodriguez has received $18.1K in total pharma payments.

How does Michael Rodriguez compare to peers in Rheumatology?

For a Rheumatologist, a single large payment from one company is less common than multiple smaller payments from various sources.

Are Michael Rodriguez's pharma relationships typical for Rheumatology?

The high concentration of payment from a single company (100%) warrants further investigation into potential conflicts of interest.

What should patients of Michael Rodriguez know about these payments?

Consumers should be aware that this doctor has received a large payment from a single drug company for consulting services, and consider this information when evaluating their treatment options.

What patterns are visible in Michael Rodriguez's payment history?

The substantial amount of the single payment ($18,052) is noteworthy for a consulting role.

Understanding This Doctor Payment Report

This transparency report for Dr. Michael Rodriguez is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:

About the Physician Payments Sunshine Act

The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.

Under this law, Dr. Michael Rodriguez's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.

The Open Payments data for Dr. Michael Rodriguez and all other physicians can be accessed at the official CMS Open Payments website.

Related Resources

Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.